Physician profile
Nellis Smith
NPI 1386678951
$2,602.59
in general payments reported to CMS, 2019-2025
22 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $71.35 · 2022: $163 · 2023: $449 · 2024: $282 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $414.26 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $371.10 | 2022-2023 | Optimizer |
| Boston Scientific Corporation | $315.54 | 2019-2024 | Rhythmia Mapping System |
| Atricure, INC. | $269.16 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Ablacon, INC. | $241.23 | 2023 | |
| Medtronic, INC. | $163.61 | 2025 | Aurora Ev-Icd Mri Surescan |
| Sanofi-Aventis U.S. LLC | $101.04 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $98.31 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Biotronik INC. | $88.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.19 | 2019 | |
| Canon Medical Systems USA, INC. | $67.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $66.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.97 | 2019 | |
| Daiichi Sankyo INC. | $47.68 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.18 | 2019 | |
| Lundbeck LLC | $24.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.81 | 2019 | |
| Novo Nordisk INC | $13.85 | 2020 | |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nellis Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.